TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36436542

Group type: EXPERIMENTAL
Intervention: Sex-informed prognostic scoring system
Number of subjects: 13284

Group type: EXPERIMENTAL
Intervention: Sex-informed genomic scoring system
Number of subjects: 13284

Group type: COMPARATOR
Intervention: Overall survival in men vs women
Number of subjects: 13284

Group type: COMPARATOR
Intervention: Overall survival in prospective validation cohorts
Number of subjects: 13284

Group type: COMPARATOR
Intervention: Overall survival in Dusseldorf MDS registry
Number of subjects: 13284
Study: 36436615

Group type: EXPERIMENTAL
Intervention: LAD V15 Gy ≥10%
Number of subjects: 449

Group type: COMPARATOR
Intervention: LAD V15 Gy <10%
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Mean heart dose ≥10 Gy
Number of subjects: 449

Group type: COMPARATOR
Intervention: Mean heart dose <10 Gy
Number of subjects: 449
Study: 36436704

Group type: EXPERIMENTAL
Intervention: Booster dose of CoronaVac (N = 134)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Booster dose of BNT162b2 (N = 133)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Booster dose of ChAdOx1 (N = 127)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Placebo (N = 129)
Number of subjects: 523
Study: 36436827

Group type: EXPERIMENTAL
Intervention: Plasma sAXL levels
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Combined use of sAXL and NT-proBNP
Number of subjects: 1030
Study: 36437124

Group type: EXPERIMENTAL
Intervention: Preoperative covert stroke
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Postoperative ischaemic brain injury
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Paired imaging analysis
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Plasma neurofilament light levels
Number of subjects: 159
Study: 36437219

Group type: EXPERIMENTAL
Intervention: Birmingham score (risk score)
Number of subjects: 276
Study: 36437418

Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine (BBIBP-CorV), 2 doses on days 0 and 21
Number of subjects: 480
Study: 36437469

Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Random Forest (RF)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Support Vector Machine (SVM)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Elastic Net (EN)
Number of subjects: 490

Group type: COMPARATOR
Intervention: L1 and L2 penalty models
Number of subjects: 490
Study: 36437696

Group type: EXPERIMENTAL
Intervention: Skin biopsy, quantitative sensory testing, tilt-table testing, painDetect, Small Fibre Neuropathy Screening List, COMPASS-31 questionnaire
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Skin biopsy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Tilt-table testing
Number of subjects: 31
Study: 36438334

Group type: EXPERIMENTAL
Intervention: Garden intervention with six standardized, raised, mulched garden beds and a Gardening Activity Guide for hands-on activities.
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Garden intervention
Number of subjects: 285

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 285

Group type: COMPARATOR
Intervention: Waitlist-control
Number of subjects: 285
Study: 36438439

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention including support for local quality improvement teams, tailored education and resources, support from kidney transplant recipients and living kidney donors, and program-level performance reports.
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 10000
Study: 36438589

Group type: EXPERIMENTAL
Intervention: Suprachoroidal injection of triamcinolone acetonide (TA) 4 mg/0.1 mL
Number of subjects: 39
Study: 36438753

Group type: EXPERIMENTAL
Intervention: Fermented PV (70 mL daily for 8 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (70 mL daily for 8 weeks)
Number of subjects: 80
Study: 36438959

Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Dim Red Light (dRL)
Number of subjects: 43
Study: 36438970

Group type: EXPERIMENTAL
Intervention: Active tVNS
Number of subjects: 116

Group type: COMPARATOR
Intervention: Sham tVNS
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Active MDB
Number of subjects: 116

Group type: COMPARATOR
Intervention: Sham MDB
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Active treatments
Number of subjects: 116

Group type: COMPARATOR
Intervention: Sham treatments
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Active tVNS and Active MDB
Number of subjects: 116

Group type: COMPARATOR
Intervention: Sham tVNS and Sham MDB
Number of subjects: 116
Study: 36439164

Group type: EXPERIMENTAL
Intervention: CCR-2, CCL-5, IL-6 expression in lymphocytes and macrophages
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlation of CCR-2 with IL-6 and IL-10
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Chronic infection process characterization
Number of subjects: 27
Study: 36439419

Group type: EXPERIMENTAL
Intervention: Supercritical extract of rosemary (SFRE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SFRE formulated with bioactive lipids
Number of subjects: 0
Study: 36439865

Group type: EXPERIMENTAL
Intervention: Motor Imagery to Facilitate Sensorimotor Re-Learning (MOTIFS) training intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Care-as-Usual (CaU) training
Number of subjects: 12
Study: 36439999

Group type: EXPERIMENTAL
Intervention: Cryoballoon (CB) ablation
Number of subjects: 29
Study: 36440011

Group type: EXPERIMENTAL
Intervention: WNT-5a
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: sFRP-5
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: WIF-1
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: WNT-5a, WIF-1
Number of subjects: 64
Study: 36440097

Group type: EXPERIMENTAL
Intervention: Candesartan (up to 32 mg once daily)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 36440464

Group type: EXPERIMENTAL
Intervention: Ligelizumab 72 mg
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Ligelizumab 240 mg
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study: 36440533

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (none, one or two doses)
Number of subjects: 2985

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (fully vaccinated)
Number of subjects: 2985

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination status and previous SARS-CoV-2 infection
Number of subjects: 2985

Group type: EXPERIMENTAL
Intervention: Age ≥ 80 years, presence of comorbidities, high care dependency
Number of subjects: 2985
Study: 36441083

Group type: EXPERIMENTAL
Intervention: Human macrophage cell therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single cell analytics
Number of subjects: 0
Study: 36441346

Group type: EXPERIMENTAL
Intervention: OCTA vascular parameters (RPC-VD%, SCP-VD%, DCP-VD%)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: PhNR amplitude
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: PhNR implicit time
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: RPC-VD and PhNR amplitude
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: SCP-VD, RNFL, and GCC thickness
Number of subjects: 152
Study: 36441357

Group type: EXPERIMENTAL
Intervention: PF-06462700 (equine anti-thymocyte immunoglobulin) administered intravenously at 40 mg/kg/day for 4 days
Number of subjects: 3
Study: 36441436

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg daily)
Number of subjects: 13
Study: 36441446

Group type: EXPERIMENTAL
Intervention: Withings Sleep Analyzer (WSA) under-mattress device for 7 nights
Number of subjects: 35

Group type: COMPARATOR
Intervention: Peripheral arterial tonometry (PAT) home sleep apnea test (HSAT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Withings Sleep Analyzer (WSA) under-mattress device
Number of subjects: 35
Study: 36441551

Group type: EXPERIMENTAL
Intervention: Family-based lifestyle program plus supervised exercise (exercise group)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Family-based lifestyle program (control group)
Number of subjects: 116
Study: 36441574

Group type: EXPERIMENTAL
Intervention: Home-based exergame intervention for 4 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard home exercise protocol
Number of subjects: 100
Study: 36441715

Group type: EXPERIMENTAL
Intervention: Fall prevention exercise
Number of subjects: 126
Study: 36441718

Group type: EXPERIMENTAL
Intervention: High cardiovascular risk (CVR) as calculated using FRESCO and REGICOR tables
Number of subjects: 962

Group type: COMPARATOR
Intervention: Low cardiovascular risk (CVR) as calculated using FRESCO and REGICOR tables
Number of subjects: 962
Study: 36441736

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (INI)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intranasal placebo (INP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral olanzapine (OLA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral placebo (PL)
Number of subjects: 32
Study: 36441798

Group type: EXPERIMENTAL
Intervention: Pertuzumab + Trastuzumab (P+T)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Pertuzumab + Trastuzumab + Paclitaxel (P+T+paclitaxel)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Gene signatures related to immune response (IR)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: BRCAness signature
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: sTILs (baseline/week 3/change)
Number of subjects: 134
Study: 36441994

Group type: EXPERIMENTAL
Intervention: MIND (8-week mindfulness-based intervention during pregnancy)
Number of subjects: 162

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 162
Study: 36442282

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 15
Study: 36442353

Group type: EXPERIMENTAL
Intervention: Anti-PD-1/PD-L1 therapy
Number of subjects: 172
Study: 36442665

Group type: EXPERIMENTAL
Intervention: Fear Potentiated Startle (FPS)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Skin Conductance Response (SCR)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Exposure-based cognitive behavioral therapy
Number of subjects: 306
Study: 36442803

Group type: EXPERIMENTAL
Intervention: Intraoperative optic nerve sheath diameter (ONSD) measured 5 minutes after reperfusion
Number of subjects: 100
Study: 36442815

Group type: EXPERIMENTAL
Intervention: Multidimensional Psychological Flexibility Inventory (MPFI)
Number of subjects: 404
Study: 36442892

Group type: EXPERIMENTAL
Intervention: Intravenous OP-724 infusion at a dosage of 280 mg/m²
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intravenous OP-724 infusion at a dosage of 380 mg/m²
Number of subjects: 7
Study: 36442911

Group type: EXPERIMENTAL
Intervention: T-cell recruiting bispecific antibodies (T-biAbs) targeting Siglec-6 and CD3, including JML-1 and RC-1.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JML-1 T-biAb
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RC-1 T-biAb
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RC-2 mAb
Number of subjects: 0
Study: 36443171

Group type: EXPERIMENTAL
Intervention: CUD-002 vaccine consisting of dendritic cells loaded with mRNA encoding personalized tumor neoantigens
Number of subjects: 0
Study: 36443208

Group type: EXPERIMENTAL
Intervention: Trans-ancestry GWAS meta-analysis
Number of subjects: 2018

Group type: COMPARATOR
Intervention: Known adult lipid loci
Number of subjects: 2018
Study: 36443400

Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 264

Group type: COMPARATOR
Intervention: No gestational diabetes mellitus (Control)
Number of subjects: 264
Study: 36443540

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 217

Group type: COMPARATOR
Intervention: Non-chemotherapy
Number of subjects: 217

Group type: COMPARATOR
Intervention: Other treatments
Number of subjects: 217
Study: 36443742

Group type: EXPERIMENTAL
Intervention: Health system readiness measures (staffing levels, glove stockouts, distance to reference laboratory)
Number of subjects: 3427

Group type: EXPERIMENTAL
Intervention: Staffing levels
Number of subjects: 3427

Group type: EXPERIMENTAL
Intervention: Glove stockouts
Number of subjects: 3427

Group type: EXPERIMENTAL
Intervention: Distance to reference laboratory
Number of subjects: 3427

Group type: EXPERIMENTAL
Intervention: Catchment area size
Number of subjects: 3427

Group type: EXPERIMENTAL
Intervention: Multiple NGOs supporting PMTCT services
Number of subjects: 3427

Group type: EXPERIMENTAL
Intervention: Facility type, stockout of prophylactic antiretrovirals, presence of quality improvement programs, mothers' support groups
Number of subjects: 3427

Group type: EXPERIMENTAL
Intervention: Positive HIV diagnosis
Number of subjects: 3427
Study: 36443816

Group type: EXPERIMENTAL
Intervention: Neutrophil extracellular traps (NET)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: PMA-activated neutrophil culture supernatant
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Neutrophil elastase (NE) and myeloperoxidase (MPO)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: NET-associated markers and fragmentation size profiles
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: NET
Number of subjects: 162

Group type: COMPARATOR
Intervention: NE KO mice
Number of subjects: 162
Study: 36443836

Group type: EXPERIMENTAL
Intervention: 12-week combined exercise programme (2 sessions/week: 30-min HIIT + 15-min resistance training)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 12-week combined exercise programme
Number of subjects: 180
Study: 36444224

Group type: EXPERIMENTAL
Intervention: Exercise intervention initiated during chemotherapy (group A)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Exercise intervention initiated after chemotherapy (group B)
Number of subjects: 266
Study: 36444227

Group type: EXPERIMENTAL
Intervention: D-VCd (daratumumab, bortezomib, cyclophosphamide, and dexamethasone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: VCd (bortezomib, cyclophosphamide, and dexamethasone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-VCd
Number of subjects: 0

Group type: COMPARATOR
Intervention: VCd
Number of subjects: 0
Study: 36444315

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 800

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 800
Study: 36444319

Group type: EXPERIMENTAL
Intervention: Systemic Coagulation-Inflammation (SCI) index
Number of subjects: 1967

Group type: EXPERIMENTAL
Intervention: Nomogram including SCI index
Number of subjects: 1967
Study: 36444331

Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy
Number of subjects: 95
Study: 36444374

Group type: EXPERIMENTAL
Intervention: BGF (budesonide/glycopyrronium/formoterol fumarate dihydrate) 320/14.4/10 µg
Number of subjects: 0
Study: 36444513

Group type: EXPERIMENTAL
Intervention: EQ VAS (per 10 unit increase)
Number of subjects: 30432

Group type: EXPERIMENTAL
Intervention: DSST (per 5 unit increase)
Number of subjects: 30432
Study: 36444764

Group type: EXPERIMENTAL
Intervention: Black Cohosh (BC) extract, treated for an average of 24.5 days (median 25; range 15-36)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 31
Study: 36444834

Group type: EXPERIMENTAL
Intervention: Unmarried patients receiving reperfusion treatment
Number of subjects: 19912

Group type: COMPARATOR
Intervention: In-hospital death
Number of subjects: 19912

Group type: COMPARATOR
Intervention: 2-year all-cause death
Number of subjects: 19912

Group type: COMPARATOR
Intervention: 2-year major adverse cardiac and cerebrovascular events (a composite of all-cause death, myocardial infarction, or stroke)
Number of subjects: 19912
Study: 36444858

Group type: EXPERIMENTAL
Intervention: Focal disease (PPG >0.73)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Diffuse disease (PPG ≤0.73)
Number of subjects: 113
Study: 36444863

Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 1498

Group type: COMPARATOR
Intervention: Patients without diabetes
Number of subjects: 1498
Study: 36444865

Group type: EXPERIMENTAL
Intervention: High-resolution ECGs measuring intra-QRS peaks (QRSp)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Prophylactic implantable cardioverter-defibrillators
Number of subjects: 143
Study: 36445158

Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve intervention (TTVI)
Number of subjects: 2628
Study: 36445230

Group type: EXPERIMENTAL
Intervention: Postpancreaticoduodenectomy (PD) with routine monitoring in ICU/IMC
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: PANCRHEMO Score 1
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: PANCRHEMO Score 2
Number of subjects: 192
Study: 36445250

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal tube (iLTS-D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambu® Auragain™
Number of subjects: 0
Study: 36445410

Group type: EXPERIMENTAL
Intervention: Intratumoral V937 + intravenous pembrolizumab 2 mg/kg Q3W
Number of subjects: 36
Study: 36445467

Group type: EXPERIMENTAL
Intervention: MTA (ProRoot WMTA)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: TotalFill
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Buccal wall thickness
Number of subjects: 108
Study: 36445668

Group type: EXPERIMENTAL
Intervention: Heart failure patients (HFrEF, HFmrEF, HFpEF)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Pulmonary arterial hypertension (PAH) patients
Number of subjects: 400
Study: 36445676

Group type: EXPERIMENTAL
Intervention: PET/CT scan for diagnosis of generator pocket infection
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: PET/CT scan for diagnosis of lead-dependent intracardiac infection
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: PET/CT scan reclassification of diagnosis
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (non-infectious indications)
Number of subjects: 21
Study: 36445734

Group type: EXPERIMENTAL
Intervention: Adhera CARINAE Digital Health Program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 60
Study: 36445882

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) and iron supplements as per guidelines
Number of subjects: 1980

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA)
Number of subjects: 1980
Study: 36445944

Group type: EXPERIMENTAL
Intervention: Fenofibrate (oral PPAR-α agonist)
Number of subjects: 30
Study: 36446040

Group type: EXPERIMENTAL
Intervention: Time-to-event continuous reassessment method (TiTE-CRM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TiTE-CRM methodology
Number of subjects: 0
Study: 36446450

Group type: EXPERIMENTAL
Intervention: Patients with COVID-19 diagnosis at discharge
Number of subjects: 6054

Group type: EXPERIMENTAL
Intervention: Patients with cardiac causes of death
Number of subjects: 6054

Group type: EXPERIMENTAL
Intervention: Patients with non-cardiovascular causes of death
Number of subjects: 6054

Group type: EXPERIMENTAL
Intervention: Patients with vascular causes of death
Number of subjects: 6054

Group type: EXPERIMENTAL
Intervention: Patients with COVID-19 related causes of death
Number of subjects: 6054
Study: 36446452

Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Surgery and adjuvant chemotherapy
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Neo-adjuvant therapy, surgery and adjuvant chemotherapy
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Post-treatment complications
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Patients' anxiety and depression
Number of subjects: 250
Study: 36446453

Group type: EXPERIMENTAL
Intervention: Genetic risk factors for acute and chronic postoperative pain
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Demographic and clinical risk factors
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Postoperative pain outcomes
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Prediction model for postoperative pain
Number of subjects: 10000
Study: 36446465

Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 7

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 7
Study: 36446481

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test (CPET) in children with asthma
Number of subjects: 446

Group type: COMPARATOR
Intervention: Cardiopulmonary exercise test (CPET) in healthy children
Number of subjects: 446
Study: 36446676

Group type: EXPERIMENTAL
Intervention: Interdisciplinary telehealth-enhanced home visits combined with peer mentoring (4 structured home visits + 16 weeks of peer mentoring)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care (historical controls)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Peer mentoring
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intervention (IN-HOME-PD)
Number of subjects: 51
Study: 36447027

Group type: EXPERIMENTAL
Intervention: Young adults with OSA
Number of subjects: 371
Study: 36447190

Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Being insured
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Cancer fatalism
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Increased age
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Reduced present orientation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Nativity (Sub-Saharan African immigrants vs African Americans)
Number of subjects: 132
Study: 36447337

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 31
Study: 36447613

Group type: EXPERIMENTAL
Intervention: Dolutegravir plus Lamivudine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36447615

Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 4664
Study: 36448227

Group type: EXPERIMENTAL
Intervention: Nelarabine continuous infusion (CI) for 5 days (120 hours) at escalating doses from 100 to 800 mg/m2
Number of subjects: 29
Study: 36448274

Group type: EXPERIMENTAL
Intervention: 10% human intravenous immunoglobulin (IVIg) BT595, total dose of 2 g/kg body weight over 2 or 5 days
Number of subjects: 34